Cleveland BioLabs

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Statera Biopharma Inc

FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate name to "Statera BioPharma, Inc." and update its ticker symbol to "STAB" effective Wednesday, September 1, 2021.

Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/.

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research.

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc.  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.

CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication in Communications Biology, a journal of Nature portfolio, describing the creation, properties and preclinical validation of efficacy of a new deimmunized and pharmacologically optimized Toll-like receptor 5 (TLR5) agonist, named GP532. The article demonstrates potency of GP532 for prophylaxis and treatment of acute radiation syndrome (ARS) in preclinical models.

Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

Akers Biosciences

Tilray Brands

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:                                                                                  CONTACT:                                                                           Joshua Rubin, Esq.                                                                               WeissLaw LLP                                                                    1500 Broadway, 16th Floor                                                                        New York, NY  10036                                                                             (212) 682-3025                                                                             (888) 593-4771                                                                   stockinfo@weisslawllp.com Newtown Lane Marketing, Inc. (OTC: NTWN) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Newtown Lane Marketing, Inc. (OTC: NTWN) in connection with the company's proposed merger with Appgate.

SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations

The stock price of Cleveland BioLabs, Inc. (NASDAQ: CBLI) is trading at over 60% pre-market. This is why it happened.

CBLI Stock Price Increases Over 60% Pre-Market: Why It Happened

FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the "Registration Statement") with...

Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - CBLI, IPHI, CBMG, WTRE, CIT

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBLI" or the "Company") (NASDAQ: CBLI) in connection with the proposed merger of the Company with...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cleveland BioLabs, Inc.

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the proposed acquisition of the company by Cytocom, Inc. Cleveland BioLabs stockholders are expected...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cleveland BioLabs, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to Cleveland BioLabs shareholders. On behalf of Cleveland BioLabs shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are a Cleveland BioLabs shareholder and would lik

Cleveland BioLabs Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cleveland BioLabs, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CBLI

New York, New York--(Newsfile Corp. - October 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cleveland BioLabs, Inc. ("BioLabs" or the "Company") (NASDAQ: CBLI) stock prior to October 20, 2020.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of BioLabs with Cytocom, Inc. ("Cytocom"). Under the terms of the merger, BioLabs stockholders will control only 39% of the combined company. To...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Cleveland BioLabs, Inc. with Cytocom, Inc. is Fair to CBLI Shareholders

Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume.

Coronavirus Link Sends This Nano-Cap Stock Up 150%

Aethlon Medical

Alpha Pro Tech

AstraZeneca

BioCryst Pharmaceuticals

Cerus

Co-Diagnostics

Inovio Pharmaceuticals

Lakeland Industries

Moderna

NanoViricides

Novavax

Vir Biotechnology

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

News for Cleveland BioLabs Stock (CBLI)